Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Guided Therapeutics Price Performance
Guided Therapeutics stock remained flat at $0.20 during midday trading on Friday. The company had a trading volume of 23,383 shares, compared to its average volume of 20,764. Guided Therapeutics has a twelve month low of $0.09 and a twelve month high of $0.54. The company has a market cap of $19.31 million, a P/E ratio of -5.00 and a beta of 0.79. The business has a 50 day moving average price of $0.23 and a two-hundred day moving average price of $0.30.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non?invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Recommended Stories
- Five stocks we like better than Guided Therapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
